Over 500 registered leaders in Charleston celebrate growth, convey recognition on four top honorees see more
To resounding applause from a record gathering from 6 countries, 26 states and virtually every county in South Carolina, more than 500 life sciences leaders at SCBIO 2022 in Charleston saluted four of their own – three individuals and one organization – for profound positive impact and exceptional contributions to the advancement of South Carolina’s life sciences industry, and the health and advancement of the state.
Attendees at the sold-out conference, delivered both live and virtually, also learned that South Carolina’s life sciences industry impact has more than doubled since 2016 – to $25.7 billion annually – and its core employment has surged more than 42% in that period despite the pandemic-induced recession of 2020.
Recipients of the Life Sciences Industry’s PINNACLE awards were the Medical University of South Carolina (MUSC) as Life Sciences Organization of the Year; Dr. Linda Bell, South Carolina state epidemiologist from SC DHEC, as Individual Contributor of the Year; Dr. Martine LaBerge of Clemson University as Life Sciences Hall of Fame recipient; and Ashley Daugherty of Nephron Pharmaceuticals as Rising Star recipient.
Clemson University’s Dr. Martine LaBerge, chair of the Clemson Department of Bioengineering, was presented with the South Carolina Life Sciences Hall of Fame Award for her personal championing of the life sciences industry, which today has 1,033 firms directly involved and over 87,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental, and agricultural biotechnology products. Clemson University is a Mission Partner of SCBIO and has been highly instrumental in helping the rapid growth of life sciences in the Palmetto State. LaBerge, who joined Clemson in 1990, is the Hall of Fame’s third member, joining former South Carolina Secretary of State Bobby Hitt and Harris Pastides, who was University of South Carolina president from 2008-2019 and recently returned as interim president.
LaBerge received her Ph.D. in biomedical engineering at the University of Montreal in Quebec and did postdoctoral work at the University of Waterloo in Ontario before joining Clemson as an assistant professor in 1990, where she rose through the ranks, became interim department chair in 2002. Deservedly credited with advancing bioengineering technology and creating interdisciplinary partnerships of scholars, entrepreneurs, and industry leaders to foster innovation, she has helped Clemson establish and strengthen strategic partnerships with the likes of Arthrex, Prisma Health and the Medical University of South Carolina. She also has played a central role in establishing new bioengineering facilities, including the Clemson University Biomedical Engineering Innovation Campus (CUBEInC) in Greenville.
Presented with the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry was MUSC Health. A Mission Partner of SCBIO, MUSC was saluted for its research, patient care and innovation in the advancement of life sciences and for its contributions during the worst of the COVID pandemic. The MUSC team was honored for its thought leadership, its educational focus in teaching future healthcare providers, its testing and vaccination campaigns to help beat back the pandemic. Accepting the award for MUSC were Dr. Pat Cawley, CEO of MUSC Health and vice president for health affairs of the Medical University of South Carolina; Dr. David Cole, President of MUSC; and Ms. Caroline Brown, Chief External Affairs Officer for MUSC.
Presented with the South Carolina Life Sciences Pinnacle Award for Individual Contribution to the industry was Dr. Linda Bell, State Epidemiologist and Director of the Bureau of Communicable Disease Prevention and Control for SC DHEC. Dr. Bell has worked in public health for over 28 years as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention with the Viral Special Pathogens Branch and as an EIS field officer. She has served in several positions with SC Department of Health and Environmental Control where, throughout the COVID-19 pandemic, she has been a lead medical advisor in South Carolina providing guidance to help control disease spread for health care
providers, elected officials, businesses, and the public.
Dr. Ashley Daugherty serves as Chief Scientific Officer for Nephron Pharmaceuticals, a rapidly growing West-Columbia based pharmaceutical organization. Dr. Daugherty joined Nephron in 2014 as a Chemist and has rapidly risen through the ranks, spending time in analytical services and product development before assuming her current role in 2019. She holds a B.Sc. in Chemistry from the University of South Carolina and her Ph.D. from Emory University in Biomolecular Chemistry. She was honored with the inaugural Rising Star Award for her contributions to product development, advancement of intellectual property initiatives, and her strong and steady leadership during the unprecedented times of the pandemic as Nephron ramped up production, added production lines, and debuted new products and services to meet critical demands of the state and country.
The four honorees were celebrated by a record 500+ registrants who filled Charleston’s Gaillard Center, with attendees including scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.
As the official state affiliate of BIO, PhRMA and AdvaMed, SCBIO members include hundreds of academic institutions, biotech companies, medtech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial, and environmental products that transform how we heal, fuel and feed the world.
New DNA-based approach may be wave of the future see more
If your doctor knew your risk for colon cancer or heart disease years before the disease developed, he or she could help you take steps to prevent it.
And by collecting DNA samples from thousands of South Carolinians, the Medical University of South Carolina is embarking on a project which hopes to do just that.
In the initiative, which stakeholders call the first of its kind in the state, MUSC is partnering with population genomics company Helix to study DNA to drive a concept known as precision medicine. It allows providers and patients to develop health care plans with a more preventive approach.
The power in precision medicine cannot be overstated, said Dr. Lori McMahon, vice president and associate provost for research at MUSC.
“Genes are what make us who we are,” she told Integrated Media, publisher of Greenville Business Magazine, Columbia Business Monthly and Charleston Business Magazine.
“What we learn here … will influence care for individuals across the country and across the globe.”
The earlier genes associated with a disease are found, the better the chances of successful treatment, said Dr. Dan Judge, professor of medicine and cardiology at MUSC and director of cardiovascular genetics.
Theoretically, this concept might have helped “Black Panther” star and Anderson, S.C., native Chadwick Boseman, he said.
Boseman died last year of colon cancer at the age of 43, seven years before traditional colonoscopy screening typically begins, he said.
Had he learned through DNA testing that he had a propensity to develop the disease, that screening could have begun much earlier, perhaps in time to keep the cancer from progressing, he said.
And a woman with a genetic predisposition to breast cancer might begin mammograms at an earlier age or get more sensitive MRIs instead, Judge said.
“We hope we’ll be saving lives with this project,” he said. “That’s really the bottom line.”
The project will focus on certain forms of cancer and cardiovascular disease initially, but hopes to expand to other diseases in time, McMahon said.
Called “In Our DNA SC,” the project hopes to enlist 100,000 South Carolina adults – 25,000 a year for four years, Judge said.
The initiative will start with MUSC patients who already have an electronic health record and an upcoming appointment, he said. They will get a message through MyChart to let them know they’re eligible. Later, it will expand across South Carolina.
“It won’t be something that private physicians can order directly,” he said. “This program requires people to sign up through a review board process so that it’s gone through protocol, and safety and confidentiality issues are all addressed.”
Similar programs have identified as many as one in 75 participants who were at risk for a serious health issue, 90 percent of which would not have been discovered through traditional practice, said Dr. James Lu, CEO and co-founder of California-based Helix, which describes itself as a population genomics company at the intersection of clinical care, research and genomics.
“By expanding access and making genomic data actionable for health care providers,” he said, “we will be able to work in tandem with MUSC … to identify risk earlier and prevent or mitigate serious diseases for its community and beyond.”
The popularity of companies like 23andme shows that people want to understand their genetics, McMahon said.
“People are even buying DNA kits for their dogs,” she said.
The genetic test is free to participants and involves only a saliva sample.
Genetic counseling will be provided to patients whose DNA reveals a risk for disease so there can be further discussion of what it means for the patient and for family members who might be at risk as well, he said.
In addition to the clinical component, the project has a research component that will develop a dataset to advance genomics research.
It also will examine how genetic changes influence the development and progression of disease, McMahon said, and help in the development of new and better therapeutics.
For instance, some people respond to certain blood pressure medications while others don’t, but it’s not understood why.
“This will help us try to understand the genetic basis for that,” she said, “and who may need alternate therapy.”
Caroline Brown, chief of external affairs at MUSC, said the hospital system and Helix took steps to ensure that patient data are secure. While the results are linked to the patient’s medical record so his provider has access to them, the information is de-identified for research purposes, she said.
The genetic results will be entered into the participants’ medical records, like a chest X-ray or MRI results are, where they are available to insurers, Judge said.
While there is a law called the Genetic Information Nondiscrimination Act that protects people from health insurance or employment discrimination on the basis of genetics, information in medical records can be used to deny life insurance or charge more for it, he said. Patients will be informed of that as part of the consent form for participation, he said.
Brown said that as a state academic medical center, MUSC is focused on building its genomics prowess to ensure it can be a leader in precision medicine in the future. It chose to partner with Helix because of its established data analytics platform which is capable of large-scale projects like this, she said.
“MUSC looked for a strategic partner to offer genetic testing that can be provided to the patient and his provider so they better know how their genetic makeup impacts their health,” she said.
MUSC has identified funding for the program, Brown said, but she declined to divulge the cost.
McMahon said that when patients and providers are armed with genetic information, they can make better decisions about care going forward and push health care to a new level.
“This is the way of the future,” she said.
And Judge said he expects it will likely be routine within 20 years.
Artificial intelligence a critical factor in improving healthcare, booming life sciences industry see more
HCA Healthcare and Google Cloud are partnering to use data analytics and artificial intelligence along with patient information in a move they say will transform health care delivery and improve outcomes.
It’s the latest step in the evolution of the fusion between health care and data.
Prisma Health recently announced a partnership with Siemens Healthineers. And the Medical University of South Carolina has been working with Siemens Healthineers for years as well as Microsoft.
Proponents say these arrangements benefit patients and providers alike. But they also raise concerns about the security of patient information.
“What they’re doing is harnessing the power of big data to drive informed change and informed decision making,” said Dr. Christine Carr, an emergency physician and senior clinical advisor with the South Carolina Hospital Association.
“Instead of a clinician on the floor saying, ‘I think this is the best way we should do our physician schedules or manage heart failure,’ we have so much data and analytic power now,” she told Integrated Media, publisher of Greenville Business Magazine, Columbia Business Monthly and Charleston Business Magazine. “It’s kind of like your iPhone, knowing where you’re going when you get in the car. We realize we have to get ahead of the disease.”
If a patient has shortness of breath, for example, providers can use data tools to predict if he has a pulmonary embolism without doing any testing, Carr said. And if he does, other tools can help determine whether he should be admitted to the hospital or sent home on medication, she said.
“The real power of using big data in health care is that it helps us deliver more efficient, high-quality care with fewer disparities,” adds Caroline Brown, chief of external affairs for MUSC and the Medical University Hospital Authority.
“There is tremendous value in marrying disparate data that lives in different places to transform the way we deliver care. There are huge benefits for patients for this data to come together,” she said. “We can practice in a more preventive way than a reactive way.”
But how accurate are these tools? Carr says they’re validated to a high degree of certainty so the clinician knows the risks.
“They are extremely accurate,” she said, adding that doctors are still the ones making the decisions.
“It delivers information but you as a human have to ultimately decide what to do,” she said. “And any unique person is a unique person. Sometimes, I just override it. And sometimes I’m right. There are still humans, for now, at the end.”
Another benefit of predictive analytics is lowering costs, Carr said.
For instance, by analyzing a patient’s information, a doctor may determine that she only needs a mammogram every three years instead of annually, she said. And it can predict the risk of hospital readmissions too, she added, “which is a big financial driver for hospitals.”
Carr speculates that all large health systems are getting into the predictive analytics space, adding that insurance companies have been using it for years to predict population health based on ZIP code, health history and socioeconomic factors.
Founded in 1968, Nashville-based HCA Healthcare is a for-profit system with some 2,000 care locations - including 186 hospitals - in 20 states and the United Kingdom.
Google Cloud, which “aims to accelerate companies’ digital transformation,” says it has business customers in more than 200 countries.
A spokesman for HCA said the company would have no comment beyond a press release and a Google spokeswoman did not return calls.
But in that release, HCA CEO Sam Hazen said that “next-generation care demands data science-informed decision support so we can more sharply focus on safe, efficient and effective patient care.”
And Google Cloud CEO Thomas Kurian said, “The cloud can be an accelerant for innovation in health, particularly in driving data interoperability, which is critical in streamlining operations and providing better quality of care to improve patient outcomes.”
Meanwhile, Adam Landau, vice president of marketing and corporate affairs for HCA’s South Atlantic Division, said in an email that it’s too early to know what the partnership will mean for its South Carolina hospitals - Colleton Medical Center in Walterboro, Grand Strand Medical Center in Myrtle Beach and Trident Health, which consists of Trident Medical Center in Charleston and Summerville Medical Center in Summerville.
“I can tell you that we’re proud to be a part of HCA Healthcare,” he said. “In combination with significant investments in mobility to support clinical care … this partnership accelerates the work of HCA Healthcare clinicians, data scientists and developers by providing highly scalable technology from Google Cloud.”
For example, he said, technology has been developed using predictive analytics that helps detect sepsis early, potentially saving lives. Another application uses clinical observations and ventilator-streamed data to reduce the length of stay for patients with acute respiratory distress syndrome (ARDS) and increase survival rates of Covid patients by 28 percent, he said.
Brown said that health care is behind other consumer-driven industries in delivering on 21st century data technology.
“One thing the … industry has been behind on is this whole consumer experience and digitalization of that over the last years,” she said. “Customers are expecting and demanding easier access to health care, they want to do so virtually from home, and in other formats that previously weren’t commonplace.”
MUSC is using data analytics to help identify gaps in care, to map workflow so the system is more efficient, and to reduce wait times for patients, among other things, she said.
A partnership with Medtronic uses more consistent monitoring technology in hospitalized patients to reduce the number of adverse respiratory events in patients prescribed opioids, she said. Another project aims to prevent hospitalizations by catching patients with heart failure and intervening earlier.
MUSC also worked with Microsoft using artificial intelligence (AI) and machine learning to detect and address potentially deadly sepsis in hospitalized patients, she said.
Prisma said its 10-year partnership with Siemens will use AI to develop algorithms to help clinicians make more informed decisions, allowing for quicker and more precise diagnoses and treatment plans.
Some of the AI will be embedded in new imaging machines as software while other AI will be developed through the partnership. Siemens will also have health economists on site studying new technologies to see if they reduce health care costs.
But with a growing number of entities gaining access to patient information, just how secure are arrangements like these?
Nationwide, the number of health information data breaches affecting 500 or more people grew from 329 in 2016 to 648 in 2020, with hacking events growing from 78 to 230 and ransomware attacks soaring from 36 to 199 during that time frame, according to the U.S. Department of Health and Human Services.
Ransomware is a multibillion-dollar industry, said James Andrew Lewis, senior vice president and director of the Strategic Technologies Program at the Center for Strategic and International Studies.
And hospitals make good targets because attackers are purely about the money and go after what will generate the most return, he added.
“You can hack a hospital and make $4 million or hack an individual and make $4,000,” he said. “These guys like bulk business. Not onesies or twosies.”
Most hospitals pay because it’s not worth the hassle, Lewis said.
Some have insurance to cover ransomware attacks. But most attackers hone in on what they think the target can afford and go for that at the hospitals that are easier to breach, he said. And if they think the hospital can pay $4 million, they’ll start out asking for $6 million, he said.
So moving to the cloud makes sense, Lewis said, because while it’s not impossible to hack, it is much more difficult and could be more secure. A lot depends on the terms of the contract, such as where the data will be stored and how it will limit the risk to privacy, he said.
Both Google and HCA say their arrangement will protect patient privacy and data by using “layers of security controls and processes” and complying with federal privacy requirements.
“The partnership is founded on strict guiding principles around privacy and security,” Landau said. “Our contract prohibits Google Cloud from the use of patient identifiable information.”
Brown said MUSC also only uses deidentified patient data for its projects. That means information like names and addresses are removed but relevant clinical data remain, subject to privacy guide rails, she said.
“Cybersecurity is a huge issue globally across all industries, and health care is no different,” she said. “Any arrangement … has to be done with utmost scrutiny to make sure patients are kept first, and commit to making sure they are protected.”
A lot of the push for these types of relationships comes from hospitals looking to solve complex health care problems on a large scale, said MUSC chief information security officer Aaron Heath.
Machine learning is helping to do that with the use of lots of data, he said, but when those two intersect, there has to be a mechanism to share the least amount of data necessary.
At the end of the day, he said, a hospital doesn’t need to put patient privacy on the hook to solve its problems.
“If we want to solve for sepsis in the hospital - detect it often and early and respond quickly - we don’t have to share patient data,” he said. “Hospitals are … only sharing the minimum amount of data to accomplish goals.”
Nonetheless, he said, it’s not without risk and hospitals need to have contracts with digital companies that prevent data from being used for any other purpose.
“There are a lot of controls we can take,” he said, “because it’s really important.”
Prisma Health said that protecting patient privacy is critical and that it has multiple systems and checks in place to safeguard it.
“As part of our Siemens Healthineers’ intelligent insights center, we will use de-identified, blinded patient data,” spokeswoman Sandy Dees said in a statement. “Under no circumstances will specific identifiers such as names, birth dates or addresses be used.”
When it comes to ransomware, hospitals are in a tough position because they can’t stop business for an attack, said Heath. MUSC has layers of defense designed to mitigate the ransomware threat so if one is breached, another kicks in, he said.
“You may not get hit by ransomware, but I can assure you your system is being targeted by phishing emails,” he said. “We are monitoring systems at all times to look for and flag potential phishing emails and get them out of our system because it’s such a common (and easy) avenue of attack. We have seen phishing emails come in to us intended to ultimately trigger an attack, but have caught them.”
A significant problem in dealing with ransomware is that most attacks come from outside the U.S. and there’s a lack of international law enforcement to allay it, Heath said.
“It’s a real challenge to stop this activity across the globe because it can be conducted from anywhere,” he said.
So MUSC invests “quite a bit” in new technology and the staff to support it, he said. And the system is constantly monitoring security and conducting training because cybercrime is a moving target that requires frequent adjustments, he said.
Still, Lewis said that ransomware “is not rocket science,” and that hospitals should be able to deal with it by backing up and encrypting data and spending more on IT to keep current.
“A big cloud provider makes you more secure. It’s their business,” he said. “Hospitals - their business is patient care, and (those) that invest proactively are better able to protect data.”
A federal health care cybersecurity task force established by HHS produced a report in 2017 that outlined ways to improve protection of health information, among them increasing the security and resilience of medical devices and health IT like electronic medical records; ensuring that the health care workforce prioritizes cybersecurity; and enhancing health care industry readiness through improved cybersecurity awareness and education.
“It’s sad we have to do this,” Lewis said. “But it’s the world we’re in and we have to pay more attention.”
SCBIO takes aim at growing the presence of women in the life sciences industry see more
While COVID-19 brought the life sciences industry squarely into the world’s spotlight, the industry has been growing rapidly around the globe — and here in South Carolina — for quite some time. From gene editing and stem cell research to health data analytics and telemedicine, amazing advances in next generation pharmaceuticals and vaccines, medical devices, diagnostics, digital health, bio-agriculture and more are reshaping our world, while also saving and improving lives.
Life sciences in South Carolina are on a growth spurt accelerated by the pandemic. The number of firms in the industry has doubled since 2017, making it the fastest-growing industry sector in the state. The Moore School of Business estimated its annual economic impact at $12 billion and over 43,000 employees — even before COVID’s surge of growth.
To fully realize the opportunity that life sciences represent for South Carolina, the Board of Directors of SCBIO have placed a priority on increasing diversity and inclusion in the industry here at home — with action replacing perfunctory policies. Those efforts are bearing fruit.
As the official life sciences industry organization for South Carolina, SCBIO has implemented a range of commitments, actions, and programs to encourage advancement for individual women and minorities, cultivate the next generations of female leaders, and strengthen and deepen the bench of talented women workers and leaders in organizations statewide.
Among SCBIO’s numerous initiatives are:
Leading by Example – Besides my role as Interim CEO, women comprise some 25% of SCBIO’s board of directors today, which is led by a female Board Chairman, Lou Kennedy, CEO and Founder of Nephron Pharmaceuticals. The Board has also launched a new Life Sciences Diversity, Equity, and Inclusion Council to support leadership development of women and minorities. The 2021-2022 SCBIO Strategic Plan for SC Life Sciences has an entire section dedicated to encouraging expanded women and minority participation in the industry.
Relationship Building – Lt. Governor Pamela Evette, Chief External Affairs Officer for MUSC Caroline Brown, and Vikor Scientific’s Partner & Co-Founder Shea Harrelson are a few of many visible leaders actively encouraging young women to expand relationships across life sciences. This network of women leaders is deep and growing, consisting of female leaders in education, manufacturing, logistics, research, medicine, government, economic development and more who reach out to support each other’s development, share ideas, problem solve and encourage skill growth.
Supporting Career Choice for Young Women – Life science jobs are not just for M.D.s and Ph.Ds, but for technical college graduates, engineers, and biology and chemistry majors as well. With an average life sciences position paying $79,000 here, SCBIO is promoting the industry as a career path to students, guidance counselors and parents at the K-12 and two- and four-year college levels. It is also developing an industry-advocated curriculum for technical colleges covering industry prescribed manufacturing processes, safety and technical protocols, soft skills and more. A recent statewide Young Women in Life Sciences ZOOM drew over 500 high school attendees from dozens of schools across the state to learn about careers in life sciences.
Connecting Young Women – Via events and community outreach such as Virtual Meetups for women in the industry and a Women in Life Sciences Visit with our Lt. Governor, SCBIO is connecting women at all levels of life sciences organizations across the state to share information on career paths, leading teams, personal development, handling difficult conversations, encouraging innovation and more to help them connect and learn together — and encourage others they know to consider the industry as a career path.
Establishing New Partnerships – New partnerships such as serving as Presenting Sponsor of Furman University’s Women’s Leadership Institute and providing scholarships at the BMW-SYNNEX 2021 Women’s Executive Luncheon create new opportunities to have life sciences as a visible part of the discussion.
Now more than ever, women in life sciences are leading the way to the industry’s rapid growth and expansion in South Carolina… and around the world. Here at home, SCBIO is working to inspire women of all ages to choose, grow and thrive in this dynamic industry by relying on, inspiring and supporting each other to attain even greater levels of success.
The future is bright and getting even brighter as more women step up to lead the way to a brighter tomorrow.